BR112012013487A2 - Composições de amantadina e métodos de uso - Google Patents

Composições de amantadina e métodos de uso

Info

Publication number
BR112012013487A2
BR112012013487A2 BR112012013487A BR112012013487A BR112012013487A2 BR 112012013487 A2 BR112012013487 A2 BR 112012013487A2 BR 112012013487 A BR112012013487 A BR 112012013487A BR 112012013487 A BR112012013487 A BR 112012013487A BR 112012013487 A2 BR112012013487 A2 BR 112012013487A2
Authority
BR
Brazil
Prior art keywords
amantadine
methods
compositions
amantadine compositions
nocturnal administration
Prior art date
Application number
BR112012013487A
Other languages
English (en)
Portuguese (pt)
Inventor
Went Greg
Sathyan Gayatri
Vermani Kavita
Ganapati Gangadhara
Coffee Michael
Shek Efraim
Original Assignee
Adamas Pharmaceuticals Inc
Ashok Katdare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44115504&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012013487(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adamas Pharmaceuticals Inc, Ashok Katdare filed Critical Adamas Pharmaceuticals Inc
Publication of BR112012013487A2 publication Critical patent/BR112012013487A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012013487A 2009-12-02 2010-12-02 Composições de amantadina e métodos de uso BR112012013487A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26605309P 2009-12-02 2009-12-02
PCT/US2010/058789 WO2011069010A2 (en) 2009-12-02 2010-12-02 Amantadine compositions and methods of use

Publications (1)

Publication Number Publication Date
BR112012013487A2 true BR112012013487A2 (pt) 2017-10-03

Family

ID=44115504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013487A BR112012013487A2 (pt) 2009-12-02 2010-12-02 Composições de amantadina e métodos de uso

Country Status (9)

Country Link
US (24) US8741343B2 (enExample)
EP (2) EP3132793A1 (enExample)
JP (4) JP5885668B2 (enExample)
CN (2) CN106389381A (enExample)
AU (1) AU2010325960C1 (enExample)
BR (1) BR112012013487A2 (enExample)
CA (2) CA2994873A1 (enExample)
MX (2) MX365650B (enExample)
WO (1) WO2011069010A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CN103181914B (zh) * 2011-12-27 2014-11-05 上海复星医药产业发展有限公司 盐酸美金刚缓释胶囊及其制备方法
CN103417483B (zh) * 2012-05-25 2017-09-12 杭州赛利药物研究所有限公司 盐酸美金刚缓释干混悬剂及其制备方法
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
SI3215132T1 (sl) * 2014-11-04 2021-11-30 Adamas Pharmaceuticals, Inc. Amantadin za izboljšanje hoje pri multipli sklerozi
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN106580923A (zh) * 2016-12-09 2017-04-26 河南中帅医药科技股份有限公司 盐酸美金刚缓释微丸、胶囊及其制备方法
WO2019040748A1 (en) * 2017-08-24 2019-02-28 Adamas Pharma, Llc AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
CN112076174B (zh) * 2020-09-04 2023-07-04 四川省百草生物药业有限公司 一种盐酸金刚乙胺片及其制备方法
US12396964B2 (en) * 2021-08-26 2025-08-26 Shinkei Therapeutics, Inc. Amantadine hydrochloride for the treatment of traumatic brain injury

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152180A (en) 1960-08-25 1964-10-06 Studiengesellschaft Kohle Mbh Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
GB1175820A (en) 1966-02-18 1969-12-23 Upjohn Co Amino-Adamantane Derivatives
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4148896A (en) 1978-02-22 1979-04-10 E. I. Du Pont De Nemours And Company Antidepressant combination
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4346112A (en) 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS584718A (ja) 1981-06-30 1983-01-11 Nippon Chibagaigii Kk 新規適応症に用うる医薬製剤
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5366738A (en) 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
JPS61502760A (ja) 1984-07-24 1986-11-27 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド 粘着性経皮投与層
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
EP0241809B1 (de) 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
ATE94384T1 (de) 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
WO1991006291A1 (fr) 1989-10-26 1991-05-16 Nippon Shinyaku Co., Ltd. Preparation a liberation entretenue
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
WO1995003052A1 (en) 1993-07-22 1995-02-02 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
KR100241300B1 (ko) 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US20020006438A1 (en) 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5677349A (en) 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
DE19528388A1 (de) 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
DE69733081T2 (de) * 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
CA2269707C (en) * 1996-10-25 2005-08-16 Edward M. Rudnic Soluble form osmotic dose delivery system
DE19644998C1 (de) 1996-10-30 1998-06-10 Hanns Prof Dr Ludwig Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
JPH10203966A (ja) 1996-11-21 1998-08-04 Takeda Chem Ind Ltd 徐放性マイクロカプセルおよびその製造法
KR20000010907A (ko) 1997-03-11 2000-02-25 야스따까 이시이 아다만탄 유도체 및 그의 제조 방법
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
DK0870757T3 (da) 1997-04-10 2002-07-15 Pfizer Fluorsubstituerede adamantanderivater
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6046232A (en) 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
EP1140012B1 (en) 1998-12-17 2004-03-03 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
JP2002535353A (ja) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
MXPA01008849A (es) 1999-03-03 2003-07-21 Optinose As Dispositivo de administracion nasal.
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
JP2003509439A (ja) 1999-09-14 2003-03-11 スミスクライン・ビーチャム・コーポレイション 水性コーティングされたビーズレットの製法
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
KR100738276B1 (ko) * 1999-12-09 2007-07-12 알자 코포레이션 항바이러스성 약제
KR100653153B1 (ko) 1999-12-22 2006-12-01 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체의 입체장애 유도체
US6753011B2 (en) 2000-01-14 2004-06-22 Osmotica Corp Combined diffusion/osmotic pumping drug delivery system
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
BR0116001A (pt) 2000-12-07 2004-07-06 Neuromolecular Inc Métodos para tratar distúrbios neuropsiquiátricos com antagonistas receptores nmda
US20040122090A1 (en) 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP5005157B2 (ja) † 2001-03-13 2012-08-22 ペンウェスト ファーマシューティカルズ カンパニー 時間治療（ｃｈｒｏｎｏｔｈｅｒａｐｅｕｔｉｃ）投与形態
US20060198815A1 (en) 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
WO2002078615A2 (en) 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US20030045577A1 (en) * 2001-08-15 2003-03-06 Madhat Maher N. Method for preventing infectious respiratory diseases
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20050271708A1 (en) 2002-03-05 2005-12-08 Thombre Avinash G Palatable controlled-release formulation for companion animals
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
EP1499289B1 (en) 2002-03-29 2008-07-23 Alza Corporation Volume efficient controlled release dosage form
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
IL165255A0 (en) 2002-05-31 2005-12-18 Lundbeck & Co As H A combination of an nmda-antagonist and acetylcholine esterase inhibitors for teh treatment of alzheimer's disease
DE10224170A1 (de) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
ATE376854T1 (de) 2002-06-26 2007-11-15 Alza Corp Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
EP1524981B1 (en) 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10237082B4 (de) * 2002-08-09 2014-12-31 Sartorius Stedim Biotech Gmbh Verfahren und Vorrichtung zur biotechnologischen Herstellung von Wertstoffen
AU2003284005B2 (en) 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
GEP20094759B (en) 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20060024366A1 (en) 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040097484A1 (en) 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2004056335A2 (es) * 2002-12-23 2004-07-08 Osmotica Costa Rica Sociedad Anonima Dispositivo de liberación que contiene venlafaxina y memantina
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
AR043467A1 (es) * 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
US20050065219A1 (en) 2003-03-27 2005-03-24 Lipton Stuart A. Treatment of demyelinating conditions
US20050124701A1 (en) 2003-06-11 2005-06-09 Went Gregory T. Method of targeting a therapeutic agent
MXPA05012810A (es) 2003-06-16 2006-02-13 Allergan Inc Formas de dosis oral de memantina.
WO2005027878A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
CA2539182A1 (en) 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20080026081A1 (en) 2003-11-21 2008-01-31 Axel Unterbeck Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050232990A1 (en) 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
WO2005072125A2 (en) 2004-01-16 2005-08-11 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
CA2554959A1 (en) 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050209218A1 (en) * 2004-02-13 2005-09-22 Meyerson Laurence R Methods and compositions for the treatment of psychiatric conditions
AU2005215767A1 (en) 2004-02-13 2005-09-01 Adamas Pharmaceuticals, Inc. Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNS disorders
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP1765305A4 (en) 2004-07-09 2008-06-04 Drugtech Corp REGULATED PHASE COMPOSITION TECHNOLOGY USED AS ENHANCED MEDICATION PROTECTION METHOD
US8609198B2 (en) * 2004-07-21 2013-12-17 Hewlett-Packard Development Company, L.P. Pharmaceutical dose form with a patterned coating and method of making the same
WO2006024018A2 (en) * 2004-08-24 2006-03-02 Neuromolecular Pharmaceuticals, Inc. Compositions for treating nociceptive pain
WO2006042249A2 (en) * 2004-10-08 2006-04-20 Neuromolecular Pharmaceuticals, Inc. Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
RU2404750C2 (ru) * 2004-11-23 2010-11-27 Адамас Фармасьютикалс, Инк. Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту
EP1845968A2 (en) 2004-11-24 2007-10-24 Neuromolecular Pharmaceuticals, Inc Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US8574626B2 (en) * 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
CA2596035A1 (en) 2005-01-28 2006-08-03 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
US20080279819A1 (en) * 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
AU2006244297A1 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of CNS disorders
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
US7951760B2 (en) * 2005-07-29 2011-05-31 Chevron Oronite S.A. Overbased alkali metal alkylhydroxybenzoates having low crude sediment
RU2385712C2 (ru) 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
EP2034980A1 (en) * 2006-05-19 2009-03-18 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of viral infections
US20080089861A1 (en) * 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
ATE510538T1 (de) * 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
AU2007291509B2 (en) 2006-08-30 2013-05-02 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
EP1961414A1 (en) 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
KR101122469B1 (ko) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
US20100092554A1 (en) 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2008151071A1 (en) 2007-05-30 2008-12-11 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
US20090041820A1 (en) 2007-08-07 2009-02-12 Wu Margaret M Functional polymer compositions
JP5204846B2 (ja) 2007-09-21 2013-06-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対して耐性を有する非オピオイド薬のｐＨ依存性制御放出医薬組成物
US20090196908A1 (en) 2008-01-31 2009-08-06 Der-Yang Lee Edible film-strips with modified release active ingredients
JP2010040238A (ja) * 2008-08-01 2010-02-18 Panasonic Corp プラズマディスプレイパネルの製造方法
US20110142905A1 (en) 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
WO2010105672A1 (en) 2009-03-18 2010-09-23 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
EP2411083A4 (en) 2009-03-23 2013-11-13 Micell Technologies Inc MEDICAL ACTIVE COMPOSITION DEVICE
WO2010115015A1 (en) 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
EP3132793A1 (en) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
EP2706641A1 (en) 2012-09-05 2014-03-12 Siemens Aktiengesellschaft Method to provide primary control power by an energy storage system
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2019040748A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE

Also Published As

Publication number Publication date
US9867791B2 (en) 2018-01-16
US20180263928A1 (en) 2018-09-20
CA2782556A1 (en) 2011-06-09
CA2994873A1 (en) 2011-06-09
US20150057355A1 (en) 2015-02-26
US20170151186A1 (en) 2017-06-01
CA2782556C (en) 2018-03-27
EP3132793A1 (en) 2017-02-22
JP2017019874A (ja) 2017-01-26
JP5885668B2 (ja) 2016-03-15
EP2506709A4 (en) 2013-05-22
US8741343B2 (en) 2014-06-03
US20110189273A1 (en) 2011-08-04
EP2506709B2 (en) 2019-10-09
US20150045448A1 (en) 2015-02-12
US20160263053A1 (en) 2016-09-15
US20170151184A1 (en) 2017-06-01
CN106389381A (zh) 2017-02-15
WO2011069010A3 (en) 2011-07-28
US20160151307A1 (en) 2016-06-02
US20170151183A1 (en) 2017-06-01
US20160263057A1 (en) 2016-09-15
WO2011069010A2 (en) 2011-06-09
JP6316376B2 (ja) 2018-04-25
US9877933B2 (en) 2018-01-30
US20160263054A1 (en) 2016-09-15
US20160263055A1 (en) 2016-09-15
JP2018100306A (ja) 2018-06-28
CN102883601A (zh) 2013-01-16
US9867792B2 (en) 2018-01-16
US11197835B2 (en) 2021-12-14
US20170151187A1 (en) 2017-06-01
US20170151190A1 (en) 2017-06-01
US20150051292A1 (en) 2015-02-19
JP2015131818A (ja) 2015-07-23
US9867793B2 (en) 2018-01-16
US20160263056A1 (en) 2016-09-15
US20200237686A1 (en) 2020-07-30
US20150045447A1 (en) 2015-02-12
US20160256414A1 (en) 2016-09-08
MX2012006320A (es) 2013-01-18
JP2013512919A (ja) 2013-04-18
MX365650B (es) 2019-06-10
AU2010325960C1 (en) 2015-08-06
US20150045439A1 (en) 2015-02-12
US20140242163A1 (en) 2014-08-28
US20170151185A1 (en) 2017-06-01
AU2010325960A1 (en) 2012-06-21
US20150045446A1 (en) 2015-02-12
JP6038203B2 (ja) 2016-12-07
AU2010325960B2 (en) 2015-02-05
EP2506709B1 (en) 2016-07-20
EP2506709A2 (en) 2012-10-10
US20150045438A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
CU20140141A7 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
MX2015008114A (es) Derivados de exendina-4.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
SV2009003236A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BRPI0710405B8 (pt) comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
BR112014027047A2 (pt) nova formulação
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
EA201590782A1 (ru) Оксирановые амины
UA112981C2 (uk) Варіант людського gdnf
PL396438A1 (pl) Wykorzystanie melatoniny do wytwarzania leku do nowego zastosowania
DOP2009000093A (es) Dihidropirazolonas sustituídas para el tratamiento de enfermedades cardiovasculares y hematológicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 33/02 , A61K 31/13

Ipc: A61K 31/13 (2006.01), A61K 31/198 (2006.01), A61P

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]